title: The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
abstract: BACKGROUND
  In the present study D2 receptor occupancy was investigated in quetiapine treated schizophrenic patients for the detection of a relationship between the scintigraphic pattern and clinical signs and symptoms.
  
  
  METHODS
  In 10 schizophrenic patients [123I]IBZM-SPECTs were performed during the introduction of quetiapine therapy (600-800 mg/day) and during a lower maintenance dose (200-400 mg/day). The patients' clinical follow-up was continued for 1 year. For the evaluation of SPECT images, visual interpretation was performed and striatum/occipital lobe (S/O) activity ratio was calculated.
  
  
  RESULTS
  The initial striatum/occipital ratio was significantly higher in patients with relapse compared to the others (1.86 +/- 0.17, 1.53 +/- 0.15, p < 0.01). The decreasing striatum/occipital ratio (increasing D2 receptor occupancy) on the 2nd SPECT was a predictive factor for the relapse.
  
  
  CONCLUSIONS
  D2 receptor occupancy and its changes during quetiapine therapy were related to the prognosis of the treatment efficacy.
authors.affiliation: Department of Nuclear Medicine, University of Szeged, Hungary. pavicsl@ss10.numed.szote.u-szeged.hu
authors.forename: Lászlo
authors.initials: L
authors.lastname: Pávics
authors.forename: György
authors.initials: G
authors.lastname: Szekeres
authors.forename: Edit
authors.initials: E
authors.lastname: Ambrus
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Kéri
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kovács
authors.forename: Miklós
authors.initials: M
authors.lastname: Argyelán
authors.forename: Balázs
authors.initials: B
authors.lastname: Kanyó
authors.forename: László
authors.initials: L
authors.lastname: Csernay
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Janka
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000493:pharmacokinetics; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D011759:Pyrrolidines / Q000493:pharmacokinetics; D000069348:Quetiapine Fumarate; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D012720:Severity of Illness Index; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D003987:Dibenzothiazepines; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; D000069348:Quetiapine Fumarate; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide